Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy
EXCLI Journal · 07.01.2026 · 25 · 102-130
DOI: 10.17179/excli2025-9020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 07.01.2026. Verfasst von Amisha S Raikar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics- PES Rajaram and Tarabai Bandekar College of Pharmacy, Ponda, Goa, 403401, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Respiratory diseases are global health challenges demanding innovative immunotherapy solutions. Toll-like receptors (TLRs) play a crucial role in immune responses, making them attractive therapeutic targets. This review examines nanoparticle-based Toll-like receptor agonists as a promising approach for respiratory immunotherapy. Nanoparticles offer targeted drug delivery and sustained release, ideal for enhancing TLR agonist efficacy. This article explores TLRs' role in immunomodulation, nanoparticle applications, design considerations, preclinical efficacy, safety assessments, challenges, and future prospects. Promising results from animal studies suggest enhanced immunological responses and reduced inflammation compared to conventional treatments. Safety concerns are addressed with insights from toxicity studies. Challenges include regulatory hurdles and biocompatibility, with strategies proposed for optimization. Nanoparticle-based TLR agonists hold great potential to transform respiratory disease treatment, warranting further research and collaboration for successful clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics- PES Rajaram and Tarabai Bandekar College of Pharmacy, Ponda, Goa, 403401, India.
- Department of Biomedical, Nutrition and Sports Sciences, Newcastle University, Newcastle upon Tyne, NE1 7RU, United Kingdom.
- Department of Biotechnology- Amity Institute of Biotechnology, Amity University, Mumbai-Pune, Maharashtra, 410206, India.
- Department of Pharmacology- PES Rajaram and Tarabai Bandekar College of Pharmacy, Ponda, Goa, 403401, India.
- Department of Pharmaceutics, Srinivas College of Pharmacy, Mangalore, Karnataka, 574143, India.
- NICM Health Research Institute and School of Science, Western Sydney University, Westmead, NSW, 2145, Australia.
Zitieren
APA
Raikar, A. S., Verma, A., Naik, M. B., Prabhu, S. M., Paudel, K. R., & Dua, K. (2026). Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy. EXCLI Journal, 25, 102-130. https://doi.org/10.17179/excli2025-9020
Vancouver
Raikar AS, Verma A, Naik MB, Prabhu SM, Paudel KR, Dua K. Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy. EXCLI Journal. 2026;25:102-130. doi:10.17179/excli2025-9020
BibTeX
@article{Raikar2026,
author = {Raikar, Amisha S and Verma, Ananya and Naik, Mayuri B and Prabhu, Sweta M and Paudel, Keshav Raj and Dua, Kamal},
title = {Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy},
journal = {EXCLI Journal},
year = {2026},
volume = {25},
pages = {102--130},
doi = {10.17179/excli2025-9020}
}
EUVIMED